Global Women Health Care Market Size & Trends & Analysis with Covid-19 Impact - Forecasts To 2026 By Drug (Actonel, Ortho Tri-Cy Lo (28), Proila, Forteo, Evista, Xgeva, Zometa, Mirena, Relcast, Primarin, Nuvaring, Minastrin 24 Fe), By Application (Hormonal Infertility, Menopause, Postmenopausal Osteoporosis, Endometriosis, Contraceptives, Polycystic Ovary Syndrome, Other Applications), By Region (North America, Europe, Asia Pacific and Rest of the World), and Company Market Share Analysis & Competitor Analysis
Women's healthcare market covers all therapies, medications, and surgical products for different diseases specific to the women's community. Women's health seeks to treat sickness better and enhance the general health of women. Some of the forces influencing the market growth are a rise in the population of women over 60, an increase in the acceptance of unhealthy lifestyle habits, and the launch of novel medicines for women. The risk of diseases such as osteoporosis, osteoarthritis, anemia, menstrual health problems, depression, and obesity is higher for women. Therefore, in the coming years, the rising incidence of these conditions is likely to fuel business growth. Moreover, increased demand for contraception to avoid unwanted pregnancies is also driving the industry's development. However, strict government regulations and many side effects are believed to have been associated with intense surgeries and drugs for women are inadequate to sustain the growth of the industry.
This market can be identified by 13 forms of drugs, such as actonel, pipeline products, forteo, minastrin 24 Fe, proila, evista, xgeva, zometa, mirena, ortho tri-cy lo (28), relcast, and primarin, nuvaring. The proila drug type is expected to contribute to a significant growth pattern in the business sector from 2020 to 2026. Owing to the rising incidence of postmenopausal osteoporosis amongst females, increasing demand for proila is a vital milestone in the development of this market segment.
This market can be served by eight categories: hormonal infertility, menopause, postmenopausal osteoporosis, endometriosis, contraception, polycystic ovary syndrome, and other applications. It is expected that the postmenopausal osteoporosis segment will contribute most to the global revenue of the sector. The growth of this group was encouraged by factors such as the increased incidence of postmenopausal osteoporosis, the pharmaceutical players' emphasis on the availability of successful postmenopausal osteoporosis medications, and the significant risk of osteoporosis fractures. Furthermore, owing to high fertility-related conditions in developing countries, the hormonal infertility segment is expected to expand rapidly. Also, the easy availability of several hormone imbalance treatment medicines and the investment of market players in new product creation will drive the growth of the segment over the forecast period.
The North American region is expected to contribute high to global revenues over the estimated period. This is due to the government's supportive legislation, acceptance and promotion of goods, and rising recognition of the importance of preserving good health, which is expected to stimulate demand growth over the forthcoming years in the North American market. Moreover, the growing incidence of PCOS and postmenopausal osteoporosis, the rise in the median age of first-time births, and increased expenditure on health care in the United States and Canada. Furthermore, the market for the Asia Pacific is ought to be growing the fastest from 2020 to 2026. This is attributed to the increasing recognition of women's well-being and health, the increasing prevalence of stress-related osteoarthritis, infertility, and other disorders, and numerous government initiatives to improve health awareness.
Major players competing are Bayer AG, Merck & Co., Allergan, Novartis AG, Lupin Limited, Ferring Pharmaceuticals, Apothecus Pharmaceutical Corporation, Amgen, Eli Lilly and Company, Pfizer, Johnson & Johnson Services Inc., Mylan NV, Agile Therapeutics, and Blairex Laboratories, Inc., among others.
Please note: This is not an exhaustive list of companies profiled in the report.
In August 2020, Bayer AG signed an agreement to acquire Kandy Therapeutics Ltd. for USD 85 million to purchase women’s health biotech.
We value your investment and offer free customization with every report to fulfil your exact research needs.
The Global Women Health Care Market has been studied from the year 2017 till 2026. However, the CAGR provided in the report is from the year 2018 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.
The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply side analysis for the Women Health Care Market.
The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.
Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the companies and customer analytics.
Tailor made solutions just for you
80% of our clients seek made-to-order reports. How do you want us to tailor yours?